Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Promise of Personalized Medicine Remains UnrealizedSeptember 15, 2011
SAN FRANCISCO, CA--(September 15, 2011) - More than a decade after completing the first draft of the human genome, the much-anticipated personalized medicine revolution that was expected to follow has been slow to unfold. Real progress is being made. But questions about the clinical utility of discoveries remain, while regulatory, financial, and policy challenges persist.
NIH Director Francis Collins and leading CEOs from companies at the forefront of personalized medicine, including Life Technologies' Greg Lucier and Illumina's Jay Flatley, will be among the speakers exploring these issues at The 7th Annual Burrill Personalized Medicine Meeting, which will be held October 3 - October 4 at the San Francisco Airport Marriott.
"Personalized medicine promises to address the high cost of drug development, improve the safety and efficacy of drugs, and ensure our healthcare dollars are better spent," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm focused on the life sciences industry. "We are at the threshold of significant change. However, real progress will only occur when clinically beneficial products are incorporated into practice. We must understand and address the impediments to doing that."
The meeting's agenda features leading authorities from across the spectrum of personalized medicine. It encourages participation, focusing on intimate discussions with small groups of panelists, expert moderators, and peers.
In addition to Collins, Lucier, and Flatley, speakers include:
Kevin Davies, Science Writer, Editor-in-Chief of "Bio-IT World" and Author of "The $1000 Genome"
Clifford Reid, CEO, Complete Genomics
Hugh Martin, CEO, Pacific Biosciences
Dietrich Stephan, President and CEO, Ignite Institute
David Gollaher, President and CEO, California Healthcare Institute
Ralph Snyderman, M.D., Chancellor Emeritus, Duke University
Pierre Cassigneul, President and CEO, XDx
Deb Kilpatrick, SVP of Commercial Operations, CardioDx
Matthew McManus, President & CEO, PrimeraDx
Stephen Little, Vice President - Personalized Healthcare, Qiagen
Matthew Rosamond, Director - Personalized Medicine Practice, PwC
Brad Stewart, Chairman, CEO and President, Cylex
Aris Persidis, President, Co-Founder, Biovista
Michael Cantor, Director, Healthcare Informatics, Pfizer
Carlos Santos, Chief Scientific Officer, Biovest International
Paul Billings, Chief Medical Officer, Life Technologies
Dr. George Poste, Chief Scientist, Complex Adaptive Systems Initiative
Additional information about The 7th Annual Burrill Personalized Medicine Meeting can be found on the Burrill & Company website at http://www.burrillandco.com/personalized_medicine_2011/. The cost of the conference is $995. Save $300 by registering online in advance of the conference for $695. Additional discounts are available for academic, government, and non-profit attendees.
You can now download the October issue of The Burrill Report, which focuses on Personalized Medicine. It is available for free at http://www.burrillreport.com/article-3868.html
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.
Burrill & Company